CoChat

Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial

BAYEVER, ELIEL, IVERSEN, PATRICK L., BISHOP, MICHAEL R., SHARP, J. GRAHAM, TEWARY, HEMANT K., ARNESON, MARK A., PIRRUCCELLO, SAMUEL J., RUDDON, RAYMOND W., KESSINGER, ANNE, ZON, GERALD, ARMITAGE, JAMES O. · 1993 · Antisense Research and Development
Cited by 149

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infusion of this compound, which is complementary to p53 mRNA. No major toxicity attributable to a dose of 0.05 mg/kg/hr was observed. A range of approximately 9 to 18% of the administered dose was recovered in the urine as intact oligonucleotide. Evaluation of malignant cells recovered from bone marrow and peripheral blood at intervals before, during, and after treatment reveals no enhanced growth potential following oligonucleotide administration. Hence, a phosphorothioate oligonucleotide complementary to p53 mRNA can be administered at this dose level to humans without major toxicity. Higher doses need to be evaluated for toxicity and potential clinical efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/ard.1993.3.383

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • p53, guardian of the genome

    Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×

    “The mutant form ofthe phosphoprotein p53 has been associated with a wide variety of human cancers (Levine et al., 1991; Lane, 1992).”

Show all 1 references

Cited by

See all 149

Metadata

Authors
BAYEVER, E., IVERSEN, P. L., BISHOP, M. R., SHARP, J. G., TEWARY, H. K., ARNESON, M. A., PIRRUCCELLO, S. J., RUDDON, R. W., KESSINGER, A., ZON, G., & ARMITAGE, J. O.
Venue
Antisense Research and Development
Published
1993-01
Volume
3
Issue
4
Pages
383-390
ISSN
1050-5261 (ISSN-L)
OpenAlex
W1447077155
Cited by
149
References
1
FWCI
10.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial. https://app.cochat.ai/papers/10.1089/ard.1993.3.383
The paper
BAYEVER, E., IVERSEN, P. L., BISHOP, M. R., SHARP, J. G., TEWARY, H. K., ARNESON, M. A., PIRRUCCELLO, S. J., RUDDON, R. W., KESSINGER, A., ZON, G., & ARMITAGE, J. O. (1993). Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial. Antisense Research and Development. https://doi.org/10.1089/ard.1993.3.383

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.